Combination of vaccination and inhibition of the pd-1 pathway
US-2016206719-A1 · Jul 21, 2016 · US
Combination of vaccination and OX40 agonists
US10307472B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10307472-B2 |
| Application number | US-201415124822-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 12, 2014 |
| Priority date | Mar 12, 2014 |
| Publication date | Jun 4, 2019 |
| Grant date | Jun 4, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a vaccine/agonist combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one OX40 agonist. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/agonist combination. Additionally the present invention relates to medical use of such a vaccine/agonist combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/agonist combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with an OX40 agonist.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treatment comprising administering to a subject in need thereof a therapeutically effective amount of: (i) at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and (ii) a composition comprising an agonistic antibody or an antigen binding fragment thereof, or a nucleic acid encoding said agonistic antibody or antigen binding fragment thereof, wherein said antibody or antigen binding from fragment thereof is directed against OX40. 2. The method of claim 1 , wherein the agonistic antibody directed against OX40 is monoclonal antibody 9B12. 3. The method of claim 1 , wherein the at least one RNA is an isolated RNA. 4. The method of claim 1 , wherein the at least one RNA is a stabilized RNA. 5. The method of claim 1 , wherein the at least one RNA is at least partially G/C modified, wherein the G/C content of the at least one open reading frame of the at least one RNA is increased compared to the wild type open reading frame. 6. The method of claim 1 , wherein the at least one RNA comprises a codon-optimized region, wherein the at least one open reading frame of the at least one RNA is codon-optimized. 7. The method of claim 1 , wherein the at least one RNA is an mRNA. 8. The method of claim 1 , wherein the at least one RNA is complexed with a carrier. 9. The method of claim 1 , wherein the agonistic antibody or an antigen binding fragment thereof, or a nucleic acid encoding said agonistic antibody or antigen binding fragment thereof is administered prior to the at least one RNA. 10. The method of claim 1 , wherein the agonistic antibody or an antigen binding fragment thereof, or a nucleic acid encoding said agonistic antibody or antigen binding fragment thereof is administered after the at least one RNA. 11. The method of claim 1 , wherein the agonistic antibody or an antigen binding fragment thereof, or a nucleic acid encoding said agonistic antibody or antigen binding fragment thereof is administered essentially simultaneously with the at least one RNA. 12. The method of claim 8 , wherein the at least one RNA is complexed with a cationic carrier. 13. The method of claim 12 , wherein the cationic carrier is a lipid.
Assignees
Inventors
Classifications
characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title
comprising antibodies · CPC title
Fusion polypeptide · CPC title
from tumour cells · CPC title
Antineoplastic agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10307472B2 cover?
- The present invention relates to a vaccine/agonist combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one OX40 agonist. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/agonis…
- Who is the assignee on this patent?
- Curevac Ag
- What technology area does this patent fall under?
- Primary CPC classification A61K39/0011. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 04 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).